Study of patients on heart pumps debunks myths about categories and outcomes

Next-generation heart pump provided superior treatment for patients, regardless of the initial intended goal of therapy

Boston, MA — A new analysis provides evidence that may change the current thinking around categorizing patients with heart failure prior to implanting a left-ventricular assist device (LVAD). Currently, clinicians and regulatory agencies divide patients who receive LVADs into two distinct categories: those receiving a device as a bridge to transplant (BTT) and those for whom the device is considered a destination therapy (DT). For BTT patients, the device is intended to extend survival until they can receive a heart transplant. For DT patients, the device is intended for long-term use. Not all patients fit neatly into these categories — many are stuck in a gray zone known as bridge to transplant candidacy (BTC). But regardless of category and the intended goal of therapy, patients who received an LVAD known as the HeartMate 3 had a similarly low rate of disabling stroke of reoperations and their outcomes were significantly better compared to patients who received an older generation LVAD. These findings, led by investigators at Brigham and Women’s Hospital, call into question the current practice of dividing patients into categories, suggesting that a single treatment goal may suffice: to extend survival and improve quality of life for patients with heart failure who haven’t responded to therapy. The team’s findings are published in JAMA Cardiology.

“This is an important analysis that could lead to a major change in thinking around adjudication of LVADs into discrete categories,” said corresponding author Mandeep Mehra, MD, Executive Director of the Brigham’s Center for Advanced Heart Disease. “We often fear that the focus on categorizing patients based on the goal of therapy, especially for patients who fall into the gray zone, may cause significant delays in decision making. Our data indicate that with the new generation LVAD, important clinical outcomes are relatively similar between these groups, suggesting that our attention should be on the patient’s journey, not the destination. We should be focused on the patient’s characteristics and identifying those who are transitioning into advanced heart failure for whom an LVAD may improve quality of life.”

The current study leverages data from the Multicenter Study of MagLev Technology in Patients
Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3), a randomized clinical trial sponsored by Abbott Laboratories, the manufacturer of HeartMate 3. MOMENTUM 3 enrolled patients irrespective of their intended goal of therapy. Patients were randomized to receive either the HeartMate II — an older generation axial flow pump — or the HeartMate 3 — a magnetically-levitated, continuous centrifugal-flow circulatory pump. The trial evaluated how many participants, two years after receiving their device, had not suffered a disabling stroke or had an operation to replace or remove a malfunctioning device.

A total of 1,020 patients received an LVAD. Of these patients, 396 (39 percent) were initially categorized by their clinicians as BTT or BTC and 624 (61 percent) were DT. Patients who received the HeartMate3 had a significantly lower rate of disabling stroke or reoperation than those who received the HeartMate II than those who received the HeartMate II in both the BTT/BTC group (77 percent versus 67 percent) and DT group (73 percent versus 59 percent). There were no differences in rates of pump thrombosis or stroke.

“The use of these designations based on current or uncertain future transplant eligibility is not necessary,” said Mehra. “Patients with medically refractory heart failure can be successfully treated under a single preimplant strategy with the goal of extending survival and improving quality of life.”

###

This study was sponsored by Abbott Laboratories. Co-authors report receiving travel support, consulting fees, research support, honoraria and grants from Abbott Laboratories. Some co-authors are employees or stakeholders in Abbott Laboratories. Mehra reported receiving travel support and consulting fees paid to Brigham and Women’s Hospital from Abbott Laboratories. A full list of disclosures is available in JAMA Cardiology.

Paper cited: Goldstein, DJ et al. “Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 Randomized Clinical Trial” JAMA Cardiology DOI: 10.1001/jamacardio.2019.5323

Brigham Health, a global leader in creating a healthier world, consists of Brigham and Women’s Hospital, Brigham and Women’s Faulkner Hospital, the Brigham and Women’s Physicians Organization and many related facilities and programs. With more than 1,000 inpatient beds, approximately 60,000 inpatient stays and 1.7 million outpatient encounters annually, Brigham Health’s 1,200 physicians provide expert care in virtually every medical and surgical specialty to patients locally, regionally and around the world. An international leader in basic, clinical and translational research, Brigham Health has nearly 5,000 scientists, including physician-investigators, renowned biomedical researchers and faculty supported by over $700 million in funding. The Brigham’s medical preeminence dates back to 1832, and now, with 19,000 employees, that rich history is the foundation for its commitment to research, innovation, and community. Boston-based Brigham and Women’s Hospital is a teaching affiliate of Harvard Medical School and dedicated to educating and training the next generation of health care professionals. For more information, resources, and to follow us on social media, please visit brighamandwomens.org.

Media Contact
Serena Bronda
[email protected]
http://dx.doi.org/10.1001/jamacardio.2019.5323

Comments